Pain Medicine, Hampton VA Medical Center, 100 Emancipation Drive, Hampton, VA, 23667, USA.
New England Mental Illness Research Education and Clinical Center (MIRECC), West Haven, CT, USA.
Curr Treat Options Oncol. 2022 Jul;23(7):921-935. doi: 10.1007/s11864-022-00985-x. Epub 2022 Apr 18.
Long-term opioid therapy (LTOT) for chronic cancer and non-cancer pain is commonly ineffective in providing its stated goal of improving function through good control of pain. Opioid tapering (slow dose reduction and/or discontinuation), the logical solution, also appears to be ineffective among many patients on LTOT as it often leads to even worse pain control and function, leaving the patients and providers managing LTOT in a clinical conundrum with little treatment choices. Complex persistent opioid dependence (CPOD) was recently offered as a heuristic to explain this clinical conundrum exemplified by the ineffectiveness of both LTOT and opioid tapering. This manuscript provides a detailed description of the neurobehavioral underpinnings of CPOD, explaining how long-term opioid use can lead to more pain even while experiencing relief with each opioid dose. CPOD is characterized by the allostatic opponent mechanisms of neuroadaptations related to the progression of opioid dependence and tolerance involving nociceptive/anti-nociceptive brain systems causing opioid-induced hyperalgesia and reward/anti-reward systems causing hyperkatefia or suffering that induces pain experience through the cognitive/emotional component of pain mechanisms. "Opioid Induced Chronic Pain syndrome" (OICP) is offered as an alternate clinical diagnostic term instead of CPOD that has several limitations as a diagnosis term including poor patient acceptance due to stigma towards addiction and clinical confounding with opioid use disorder, a related but separate clinical entity. OICP with LTOT is conceptualized as a recoverable iatrogenic problem that can be managed by pain providers. Broad guidance on management of OICP is also provided.
长期阿片类药物治疗(LTOT)用于慢性癌痛和非癌痛,通常无法有效实现通过良好的疼痛控制来改善功能的既定目标。阿片类药物减量(缓慢剂量减少和/或停药),作为一种合理的解决方案,在许多接受 LTOT 的患者中似乎也无效,因为它通常会导致更差的疼痛控制和功能,使患者和提供者在 LTOT 的管理中陷入临床困境,治疗选择有限。复杂的持续性阿片类药物依赖(CPOD)最近被提出作为一种启发式方法,以解释 LTOT 和阿片类药物减量都无效的这种临床困境。本文详细描述了 CPOD 的神经行为基础,解释了长期使用阿片类药物如何导致更多的疼痛,尽管每次使用阿片类药物都会感到缓解。CPOD 的特征是与阿片类药物依赖和耐受进展相关的神经适应的对立机制,涉及伤害感受/抗伤害感受大脑系统导致阿片类药物引起的痛觉过敏和奖励/抗奖励系统导致快感或痛苦,通过疼痛机制的认知/情感成分引起疼痛体验。“阿片类药物引起的慢性疼痛综合征”(OICP)被提出作为一个替代的临床诊断术语,而 CPOD 作为一个诊断术语有几个局限性,包括由于对成瘾的污名化和与阿片类药物使用障碍的临床混淆,导致患者接受度差,阿片类药物使用障碍是一种相关但独立的临床实体。LTOT 伴 OICP 被概念化为一种可恢复的医源性问题,可以由疼痛提供者管理。还提供了 OICP 管理的广泛指导。